Search
01/07/2022
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021) (vol 24, pg 712, 2022)
Majem, M, de las Penas, R, Virizuela, JA, Cabezon-Gutierrez, L, Cruz, P, Lopez-Castro, R, Mendez, M, Mondejar, R, Munoz, MD, Escobar, Y. SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021) (vol 24, pg 712, 2022). Clinical & Translational Oncology. 2022; 24(7)DOI:10.1007/s12094-022-02846-3. PMID:35567734. IF:3.400(Q3/6D).
01/07/2022
Cabozantinib for the treatment of solid tumors: a systematic review
Maroto, P, Porta, C, Capdevila, J, Apolo, AB, Viteri, S, Rodriguez-Antona, C, Martin, L, Castellano, D. Cabozantinib for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14DOI:10.1177/17588359221107112. PMID:35847482. IF:4.900(Q2/4D).
01/07/2022
Cabozantinib combination therapy for the treatment of solid tumors: a systematic review
Castellano, D, Apolo, AB, Porta, C, Capdevila, J, Viteri, S, Rodriguez-Antona, C, Martin, L, Maroto, P. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14DOI:10.1177/17588359221108691. PMID:35923927. IF:4.900(Q2/4D).
01/07/2022
Involvement of the PI3K/AKT Intracellular Signaling Pathway in the AntiCancer Activity of Hydroxytyrosol, a Polyphenol from Olea europaea, in Hematological Cells and Implication of HSP60 Levels in Its Anti-Inflammatory Activity
Parra-Perez, AM, Perez-Jimenez, A, Gris-Cardenas, I, Bonel-Perez, GC, Carrasco-Diaz, LM, Mokhtari, K, Garcia-Salguero, L, Lupianez, JA, Rufino-Palomares, EE. Involvement of the PI3K/AKT Intracellular Signaling Pathway in the AntiCancer Activity of Hydroxytyrosol, a Polyphenol from Olea europaea, in Hematological Cells and Implication of HSP60 Levels in Its Anti-Inflammatory Activity. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(13)DOI:10.3390/ijms23137053. PMID:35806065. IF:5.600(Q1/3D).
01/07/2022
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Alvarez-Larran, A, Garrote, M, Ferrer-Marin, F, Perez-Encinas, M, Mata-Vazquez, MI, Bellosillo, B, Arellano-Rodrigo, E, Gomez, M, Garcia, R, Garcia-Gutierrez, V, Gasior, M, Cuevas, B, Angona, A, Gomez-Casares, MT, Martinez, CM, Magro, E, Ayala, R, del Orbe-Barreto, R, Perez-Lopez, R, Fox, ML, Raya, JM, Guerrero, L, Garcia-Hernandez, C, Caballero, G, Murillo, I, Xicoy, B, Ramirez, MJ, Carreno-Tarragona, G, Hernandez-Boluda, JC, Pereira, A. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. CANCER. 2022; 128(13)DOI:10.1002/cncr.34195. PMID:35417564. IF:6.200(Q1/3D).
01/07/2022
Causes of long-term mortality in patients with head and neck squamous cell carcinomas
Lop, J, Venegas, MD, Pujol, A, Sauter, B, Vasquez, R, Casasayas, M, Quer, M, Leon, X. Causes of long-term mortality in patients with head and neck squamous cell carcinomas. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY. 2022; 279(7)DOI:10.1007/s00405-021-07211-8. PMID:34905065. IF:2.600(Q2/3D).